Shares of Becton Dickinson & Co. BDX slipped 2.13% to $221.59 Thursday, on what proved to be an all-around dismal trading ...

Becton Dickinson (BDX) explores divesting its $21B life sciences unit, engaging with rivals like Thermo Fisher (TMO) & ...

Buy rating initiated! Discover why this medtech leader with strong growth prospects & dividends is worth your attention.

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The firm is not ...

Becton, Dickinson and Co. also reported slightly higher pay for the device developer and manufacturer's median worker in ...

In February the company had announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, ...

River Road Asset Management, an investment management company released its “River Road Large Cap Value Select Fund” Q4 2024 ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Tuesday. A number of other ...

Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have received an average recommendation of “Buy” from the seven research firms that are currently covering the firm ...

In addition to job gains, local leaders see Arizona emerging as one of the nation’s most dynamic hubs for bioscience ...

To enable knowledge sharing for laboratory personnel on technological advancement and best practices made towards assessment ...

U.S. medical device maker Becton Dickinson is in talks with Thermo Fisher and Danaher for a potential sale of its life sciences unit, the Financial Times reported on Tuesday. Becton Dickinson had in ...